Nano cap stock NovaBay Pharmaceuticals $NBY, which in normally thinly traded, vaulted 14% in early hours after it announced positive results from a Phase 2 b clinical trial evaluating its Auriclosene Irrigating Solution (AIS) (NVC-422) meant for thwarting catheter blockage in patients suffering from chronic indwelling urinary catheters.